This content is for informational purposes only and is not a substitute for professional advice.
A mitochondria-support stack should be built like a conservative supplement stack: one clear goal, one primary metric, transparent doses, slow review windows, and no claims that supplements repair mitochondrial disease or treat unexplained fatigue.
Mitochondria are not a vibe. They are cellular organelles involved in ATP production, redox signaling, heat generation, calcium handling, apoptosis, and metabolic sensing. That makes them attractive to supplement marketers and difficult for self-experimenters. A product can sound "mitochondrial" because it touches a pathway in a cell model, then fail to produce a measurable human outcome at a real-world dose.
The useful question for an Unfair protocol is narrower: does a specific ingredient improve a specific energy, training, recovery, or cognition metric in you, at a tolerable dose, under stable conditions?
What this stack is for
This guide is for generally healthy adults who want to test non-stimulant support for perceived energy, training quality, recovery, or cognitive stamina. It is not a protocol for mitochondrial disease, chronic unexplained fatigue, neurologic disease, cardiovascular disease, diabetes, anemia, thyroid disease, sleep apnea, long COVID, pregnancy, or medication-managed conditions.
If fatigue is new, severe, persistent, or paired with chest pain, fainting, shortness of breath, unintentional weight loss, fever, blood loss, major mood change, or abnormal labs, the next step is medical evaluation, not a larger stack.
Methodology
Candidates were ranked using four filters.
First, human evidence mattered more than mechanistic appeal. Compounds with plausible mitochondrial mechanisms but thin human outcome data were treated as experimental, even when the pathway story sounded elegant.
Second, the endpoint had to be testable at home. Training volume, repeat-effort performance, afternoon fatigue, recovery rating, sleep quality, resting heart rate, and fixed cognitive tasks are imperfect, yet they can be collected repeatedly. "Mitochondrial health" by itself is not a home endpoint.
Third, safety and interaction load counted heavily. A low-risk ingredient with a modest but trackable effect can be a better stack candidate than a more exotic compound with unclear product quality, unclear dosing, or meaningful medication concerns.
Fourth, attribution mattered. Combination formulas were downgraded because they make it hard to know whether creatine, CoQ10, caffeine contamination, B vitamins, or expectancy produced the result.
Evidence table
| Candidate | Best-fit role | Evidence read | Conservative test window | Main cautions |
|---|---|---|---|---|
| Creatine monohydrate | Training output, repeat high-intensity work, possible cognitive stamina in selected contexts | Strong for exercise performance; mixed but plausible for cognition depending on contextcreatinecreatine-cognition | 6 weeks at a stable daily dose | GI symptoms, water-weight changes, kidney-disease context, creatinine lab interpretation |
| CoQ10 | Non-stimulant fatigue or exercise-recovery trial, especially when there is a specific reason to test it | Moderate for fatigue outcomes across mixed populations; not a general energy guaranteecoq10-nccihcoq10-fatigue | 4 to 8 weeks with meal-consistent dosing | Warfarin and anticoagulant context, blood-pressure or diabetes medications, cancer-treatment context |
| PQQ | Experimental add-on after CoQ10 has been tested alone | Limited human outcome data; mechanistic interest exceeds practical certaintypqq | 4 to 8 weeks as a separate phase | Product quality, insomnia or GI symptoms, weak attribution in formulas |
| Acetyl-L-carnitine | Mental fatigue or exercise-fatigue trial where the goal is clearly defined | Limited to moderate depending on population; general wellness evidence is not settled | 4 to 8 weeks | Fishy odor, GI symptoms, agitation or insomnia in some users, seizure-disorder caution |
| Magnesium | Deficiency-risk, low intake, sleep quality, muscle cramp context, or medication-depletion context | Strong as an essential nutrient; supplement benefit is most convincing when intake or status is lowmagnesium | 2 to 6 weeks | Diarrhea, nausea, supplemental upper limit, kidney disease, separation from some antibiotics and thyroid medication |
| B vitamins | Correction of deficiency risk, diet gaps, metformin or PPI context for B12, high alcohol intake or restricted diets | Strong for correcting deficiency; weak as a blanket energy enhancer when status is adequateb12b6 | 4 to 12 weeks, ideally with labs when relevant | High B6 can cause neuropathy; niacin flushing and liver risk at high doses; folic acid can mask B12 deficiency |
| Alpha-lipoic acid | Experimental metabolic or redox-support trial, usually not first-line | Human evidence is stronger in clinical neuropathy and metabolic contexts than in healthy energy trialsala-safety | 4 to 8 weeks | Blood-glucose lowering potential, GI symptoms, thyroid-medication context, alcohol/thiamine risk context |
Stack design rules
Start with the least romantic layer: sleep duration, total energy intake, protein, carbohydrate around training, iron status when relevant, B12 status when risk is present, and magnesium intake. Many "mitochondria stack" failures are basic fueling or deficiency problems dressed in advanced language.
Then choose one primary outcome. Good examples are afternoon fatigue, repeat sprint drop-off, completed training volume at a fixed RPE, recovery rating after comparable sessions, or performance on one fixed cognitive task. Poor examples are "cellular energy," "vitality," or "mitochondria feel."
Add only one new active ingredient per phase. If you start creatine, CoQ10, PQQ, acetyl-L-carnitine, and a B-complex together, every positive and negative result becomes a story instead of a finding.
Prefer transparent single-ingredient products. Avoid proprietary "mitochondrial complex" formulas when testing. A premade product may be convenient after you already know what works, but it is a poor discovery tool.
Use the lowest boring dose that matches studied or conventional ranges, then hold it steady. The goal is not to feel pharmacology on day one. The goal is to see whether a stable protocol changes a stable metric.
A conservative starting architecture
The safest structure is foundation, candidate, review.
Foundation means correcting obvious gaps before adding specialty compounds. For many people, that means no new mitochondrial product at all until sleep, food, hydration, training load, caffeine timing, and relevant labs have been reviewed.
Candidate means a single test ingredient. Creatine is usually the strongest first candidate if the goal includes training output, repeat-effort performance, or recovery from resistance training. CoQ10 is a more reasonable first candidate when the goal is non-stimulant fatigue tracking and the person understands that the expected effect is modest and slow. Magnesium or B vitamins belong first when intake, diet pattern, medication context, or labs make adequacy the main question.
Review means deciding from data. Keep, change timing, reduce dose, pause, or remove. Do not keep a supplement simply because it is biologically plausible.
| Goal | First test | Why | What not to add during the phase |
|---|---|---|---|
| More repeat training output | Creatine monohydrate | Stronger human performance evidence and simple dosing | New pre-workout, beta-alanine, stimulant formulas |
| Less afternoon fatigue | CoQ10 or magnesium if intake is low | Non-stimulant test with a slow review window | PQQ, acetyl-L-carnitine, caffeine changes |
| Better recovery after training | Creatine or CoQ10 | Trackable against training logs and soreness ratings | New recovery formulas, tart cherry, high-dose antioxidants |
| Diet-risk correction | B12, folate, riboflavin, or magnesium based on risk | Deficiency correction is more defensible than broad "energy" dosing | High-dose B-complex without a reason |
| Experimental mitochondrial add-on | PQQ after a completed CoQ10 phase | Keeps attribution clean | Starting PQQ and CoQ10 together |
Safety cautions
Mitochondria marketing often makes supplements sound foundational enough to be universally safe. That is not how risk works. Risk comes from dose, product quality, medical context, medications, pregnancy status, kidney and liver function, psychiatric history, seizure history, and the total stack.nccih-interactions
CoQ10 can interact with warfarin and may be relevant around insulin, blood-pressure medication, and some cancer-treatment contexts. Do not self-test CoQ10 in those settings without a clinician or pharmacist.
Magnesium from supplements can cause diarrhea, nausea, and cramping, and high supplemental intake is treated differently from magnesium in food. Kidney disease changes the safety picture because magnesium clearance can be impaired.
B vitamins are not automatically harmless because they are water-soluble. High B6 intake can cause neuropathy. High-dose niacin can cause flushing and, at pharmacologic doses, liver risk. Folate can improve blood markers while leaving B12 deficiency unresolved, which can delay recognition of neurologic risk.
Alpha-lipoic acid may lower blood glucose and has special caution around diabetes medication, thyroid medication, heavy alcohol use, and poor thiamine status.
Acetyl-L-carnitine can be stimulating for some people. If it worsens sleep, agitation, or anxiety, it has failed the stack even if it has an appealing mechanism.
Stop immediately for allergic symptoms, chest pain, fainting, severe dizziness, new neurologic symptoms, severe insomnia, persistent vomiting or diarrhea, or any clinician-directed warning. Pause interpretation whenever medications, major diet changes, illness, training load, or sleep schedule change during the test.
How to test this in Unfair
Create a protocol named after the ingredient and endpoint, such as "CoQ10 afternoon fatigue" or "Creatine repeat sets." The name should make the hypothesis obvious before you look at the data.
Run a 14-day baseline with no new supplements. Log the primary metric daily or on every training day, then log the confounders that most often distort energy data: sleep duration, sleep quality, caffeine total, final caffeine time, alcohol, training load, illness, menstrual cycle phase when relevant, and meal timing.
Set one active window. Creatine usually deserves 42 days. CoQ10, PQQ, acetyl-L-carnitine, and alpha-lipoic acid usually deserve 4 to 8 weeks. Magnesium can be reviewed after 2 to 6 weeks depending on the endpoint. B vitamins should be tied to diet risk or lab context and reviewed more slowly.
Add stop rules before the first dose. Useful stop rules include sleep quality down 2 or more points for 3 nights, resting heart rate 10 or more bpm above baseline for 3 days, GI symptoms for more than 3 days, new anxiety or agitation for 3 days, or any allergic symptoms.
At review, compare baseline, active, and any washout period. Unfair should mark the result as "useful," "uncertain," or "remove." A useful result needs a meaningful benefit, tolerable side effects, good adherence, and no obvious confounder explanation. An uncertain result is still progress because it prevents the stack from becoming permanent folklore.
Sources
This article is for education only and does not substitute for professional medical advice.
Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017;14:18. https://pubmed.ncbi.nlm.nih.gov/28615996/
↩Avgerinos KI, Spyrou N, Bougioukas KI, Kapogiannis D. Effects of creatine supplementation on cognitive function of healthy individuals: a systematic review of randomized controlled trials. Exp Gerontol. 2018;108:166-173. https://pubmed.ncbi.nlm.nih.gov/29704637/
↩NIH National Center for Complementary and Integrative Health. Coenzyme Q10. https://www.nccih.nih.gov/health/coenzyme-q10
↩Tsai IC, Hsu CW, Chang CH, Tseng PT, Chang KV. Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9449413/
↩Harris CB, Chowanadisai W, Mishchuk DO, et al. Dietary pyrroloquinoline quinone alters indicators of inflammation and mitochondrial-related metabolism in human subjects. J Nutr Biochem. 2013. https://pubmed.ncbi.nlm.nih.gov/23830056/
↩National Institutes of Health, Office of Dietary Supplements. Magnesium: Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
↩National Institutes of Health, Office of Dietary Supplements. Vitamin B12: Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
↩National Institutes of Health, Office of Dietary Supplements. Vitamin B6: Fact Sheet for Consumers. https://ods.od.nih.gov/factsheets/VitaminB6-Consumer/
↩Akbari M, Ostadmohammadi V, Tabrizi R, et al. Safety Evaluation of alpha-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. Antioxidants. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7603186/
↩NIH National Center for Complementary and Integrative Health. How Medications and Supplements Can Interact. https://www.nccih.nih.gov/health/know-science/how-medications-supplements-interact
↩